Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

NCT00988169 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: oral erlotinib and pulsed doses of oral AT-101

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]